Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CKD-351 in Glaucoma and Ocular Hypertension
NCT03762369Phase 3Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2018
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of latanoprost, dorzolamide in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
latanoprostdorzolamide
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03762369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762369.